Nice try._老虎社区_美港股上老虎

rhmnjfr
2021-11-03

Nice try.

2 Meme Stocks With Short Squeeze Potential In November

Wall Street Memes lists two meme stocks that might be on the verge of a short squeeze. Will OCGN and

2 Meme Stocks With Short Squeeze Potential In November

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":848084998,"tweetId":"848084998","gmtCreate":1635948364567,"gmtModify":1635948371342,"author":{"id":3575552457926722,"idStr":"3575552457926722","authorId":3575552457926722,"authorIdStr":"3575552457926722","name":"rhmnjfr","avatar":"https://static.tigerbbs.com/c38827a746715f9db0eee24ada0d72b7","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice try.</p></body></html>","htmlText":"<html><head></head><body><p>Nice try.</p></body></html>","text":"Nice try.","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/848084998","repostId":1194203181,"repostType":4,"repost":{"id":"1194203181","kind":"news","pubTimestamp":1635942663,"share":"https://www.laohu8.com/m/news/1194203181?lang=&edition=full","pubTime":"2021-11-03 20:31","market":"us","language":"en","title":"2 Meme Stocks With Short Squeeze Potential In November","url":"https://stock-news.laohu8.com/highlight/detail?id=1194203181","media":"TheStreet","summary":"Wall Street Memes lists two meme stocks that might be on the verge of a short squeeze. Will OCGN and","content":"<p>Wall Street Memes lists two meme stocks that might be on the verge of a short squeeze. Will OCGN and PROG head to the moon in November?</p>\n<p>“Meme frenzy” may seem to be hibernating, but it is certainly still alive under the sheets. Retail investors continue to monitor and debate several key stocks on the main discussion boards across the web, and some have started to move in the past few days – think GameStop&nbsp;on November 1, for example.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c8a435559be38d10b7251aa72e23a665\" tg-width=\"1240\" tg-height=\"698\" width=\"100%\" height=\"auto\"><span>Figure 1: Ocugen and Progenity logo.</span></p>\n<p>Driven by popularity, momentum and elevated short interest, Wall Street Memes lists two meme stocks that have “mooning” potential in November.</p>\n<p><b>1. Ocugen, Inc.</b></p>\n<p>Biopharmaceutical company Ocugen, which focuses mainly on gene therapies to cure blindness diseases, had its ticker trending multiple times since the beginning of October.</p>\n<p>The company has become a meme focus and nearly doubled in price in the past few trading days.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3e281fc931d00e6aa06e33fd23394521\" tg-width=\"547\" tg-height=\"557\" width=\"100%\" height=\"auto\"><span>Figure 2: OCGN stock sentiment on WSB.</span></p>\n<p>The most likely&nbsp;catalyst&nbsp;behind the price surge is the&nbsp;anticipated&nbsp;World Health Organization’s approval of COVID-19 vaccine Covaxin.</p>\n<p>Ocugen is a co-development partner with Bharat Biotech on the drug, and it holds the rights to commercialize Covaxin in North America. Recent&nbsp;stage 3 results&nbsp;showed the drug to be efficient even against the delta variant, which could help in the approval process in these countries.</p>\n<p>Meanwhile, the stock is a bear&nbsp;target. OCGN has 56 million shares shorted, representing a whopping 29% of the float. While heavy shorting signals skepticism and caution, it can also put shares on the edge of a short squeeze — if or once massive buying volume takes place.</p>\n<p>The eventual vaccine approval could be the catalyst that sparks bullish short-term activity. The binary nature of this trade, however, offers much complexity and risk to both longs and shorts.</p>\n<p><b>2. Progenity</b></p>\n<p>Progenity&nbsp;(<b>PROG</b>)&nbsp;is a biotechnology company that develops molecular testing products in the US. With a market cap of $284 million, the company went public last year at $14 per share. Since then, share price has plummeted to below $1, giving PROG the infamous label of “penny stock”.</p>\n<p>In the past month, PROG has spiked around 130%. As short interest on the stock climbed, the volume of comments on major web forums increased as well. Currently, according to Yahoo Finance’s latest&nbsp;data, nearly 24% of the float its being shorted.</p>\n<p>Based on the company’s fundamentals, H.C. Wainwright’s Joseph Pantginis recently issued a report on PROG. The analyst&nbsp;started&nbsp;his coverage with a buy rating and 27% upside potential. His bull case is based on the company’s differentiated portfolio and the opportunities that it offers.</p>\n<blockquote>\n <i>\"Progenity</i>’\n <i>s differentiated R&amp;D pipeline primarily focuses on employing proprietary ingestible device technologies, in tandem with delivery of de-risked</i>&nbsp;\n <i>FDA</i>&nbsp;\n <i>approved therapies.”</i>\n</blockquote>\n<p>PROG’s popularity remains high, backed by Reddit forum discussions. Short interest is still elevated, despite the rally last month. This setup could lead the stock to a short squeeze.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0998a8e99f6ddce996a329ba5c7a179c\" tg-width=\"1076\" tg-height=\"405\" width=\"100%\" height=\"auto\"><span>Figure 3: Trending stocks on Reddit on November 2.</span></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Meme Stocks With Short Squeeze Potential In November</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Meme Stocks With Short Squeeze Potential In November\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-03 20:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/2-meme-stocks-with-short-squeeze-potential-in-november><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street Memes lists two meme stocks that might be on the verge of a short squeeze. Will OCGN and PROG head to the moon in November?\n“Meme frenzy” may seem to be hibernating, but it is certainly ...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/2-meme-stocks-with-short-squeeze-potential-in-november\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.thestreet.com/memestocks/other-memes/2-meme-stocks-with-short-squeeze-potential-in-november","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194203181","content_text":"Wall Street Memes lists two meme stocks that might be on the verge of a short squeeze. Will OCGN and PROG head to the moon in November?\n“Meme frenzy” may seem to be hibernating, but it is certainly still alive under the sheets. Retail investors continue to monitor and debate several key stocks on the main discussion boards across the web, and some have started to move in the past few days – think GameStop on November 1, for example.\nFigure 1: Ocugen and Progenity logo.\nDriven by popularity, momentum and elevated short interest, Wall Street Memes lists two meme stocks that have “mooning” potential in November.\n1. Ocugen, Inc.\nBiopharmaceutical company Ocugen, which focuses mainly on gene therapies to cure blindness diseases, had its ticker trending multiple times since the beginning of October.\nThe company has become a meme focus and nearly doubled in price in the past few trading days.\nFigure 2: OCGN stock sentiment on WSB.\nThe most likely catalyst behind the price surge is the anticipated World Health Organization’s approval of COVID-19 vaccine Covaxin.\nOcugen is a co-development partner with Bharat Biotech on the drug, and it holds the rights to commercialize Covaxin in North America. Recent stage 3 results showed the drug to be efficient even against the delta variant, which could help in the approval process in these countries.\nMeanwhile, the stock is a bear target. OCGN has 56 million shares shorted, representing a whopping 29% of the float. While heavy shorting signals skepticism and caution, it can also put shares on the edge of a short squeeze — if or once massive buying volume takes place.\nThe eventual vaccine approval could be the catalyst that sparks bullish short-term activity. The binary nature of this trade, however, offers much complexity and risk to both longs and shorts.\n2. Progenity\nProgenity (PROG) is a biotechnology company that develops molecular testing products in the US. With a market cap of $284 million, the company went public last year at $14 per share. Since then, share price has plummeted to below $1, giving PROG the infamous label of “penny stock”.\nIn the past month, PROG has spiked around 130%. As short interest on the stock climbed, the volume of comments on major web forums increased as well. Currently, according to Yahoo Finance’s latest data, nearly 24% of the float its being shorted.\nBased on the company’s fundamentals, H.C. Wainwright’s Joseph Pantginis recently issued a report on PROG. The analyst started his coverage with a buy rating and 27% upside potential. His bull case is based on the company’s differentiated portfolio and the opportunities that it offers.\n\n\"Progenity’\n s differentiated R&D pipeline primarily focuses on employing proprietary ingestible device technologies, in tandem with delivery of de-risked \n FDA \n approved therapies.”\n\nPROG’s popularity remains high, backed by Reddit forum discussions. Short interest is still elevated, despite the rally last month. This setup could lead the stock to a short squeeze.\nFigure 3: Trending stocks on Reddit on November 2.","news_type":1},"isVote":1,"tweetType":1,"viewCount":933,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}